ACD ENTERS AGREEMENT WITH ULTRAGENYX TO INVEST IN CLINICAL DEVELOPMENT OF THERAPY FOR CREATINE TRANSPORTER DEFICIENCY
ACD commits $4 million investment with Ultragenyx to accelerate path to treatment for CTD patients CARLSBAD, CA, UNITED STATES, July 2, 2026 /EINPresswire.com/ -- The Association for Creatine Deficiencies (ACD) today announced it has entered …